Proteon Therapeutics

Last updated
Proteon Therapeutics
Type Public
Nasdaq:  PRTO
Russell Microcap Index component
Industry Pharmaceuticals
Founded1 January 2001  OOjs UI icon edit-ltr-progressive.svg
Headquarters
Waltham   OOjs UI icon edit-ltr-progressive.svg
,
United States  OOjs UI icon edit-ltr-progressive.svg
Website www.proteontherapeutics.com

Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.

Contents

Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company. [1]

The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing. [2]

On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. [3] The company went public in 2014. [4]

In September 2019, Proteon Therapeutics merged with ArTara Therapeutics. [5] [6]

PRT-201

Proteon is developing PRT-201 (vonapanitase), a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). PRT-201 is a recombinant human elastase [7] manufactured for Proteon by Lonza. [8]

In September 2008, the company announced that the Food and Drug Administration had granted fast track status to PRT-201. In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%. [9]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States. It is one of the largest pharmaceutical companies in the world.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Pharmaceutical company in Asia

The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

<span class="mw-page-title-main">Alcon</span> American Based Eye Pharmaceutical Company

Alcon is an American Swiss medical company specializing in eye care products with headquarters in Geneva, Switzerland, and incorporated in Fribourg, Switzerland. Alcon began as a US company and its US subsidiary’s headquarters remain in Fort Worth, Texas, where the Alcon division of the company was founded.

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York.

Repros Therapeutics Inc. (Nasdaq: RPRX), was a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski was the CEO of this company.

Phillip Frost is an American entrepreneur.

Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015, with $280 million in commitments.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has eight products in its pipeline, in various stages of development.

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

<span class="mw-page-title-main">Intellia Therapeutics</span> Biotechnology company

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys. The company has partnerships with Novartis and Regeneron.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods.

References

  1. ↑ Roberts, Rob (April 5, 2007). "Proteon secures $12M in financing". Kansas City Business Journal. Retrieved 2008-07-27.
  2. ↑ "About". Proteontherapeutics.com. Retrieved 2017-02-28.
  3. ↑ "Proteon raises $38m, signs option deal with Novartis". The Boston Globe. March 5, 2009.
  4. ↑ "SEC Filings | Proteon Therapeutics Inc". Ir.proteontherapeutics.com. Retrieved 2017-02-28.
  5. ↑ "Proteon announces merger with ArTara Therapeutics, $42.5M stock purchase". www.spglobal.com. Retrieved 2020-04-17.
  6. ↑ "Proteon Therapeutics to merge with ArTara Therapeutics". www.pharmaceutical-technology.com. 23 September 2019. Retrieved 2020-04-17.
  7. ↑ "VONAPANITASE FOR RADIOCEPHALIC FISTULAS". Phx.corporate-ir.net. Retrieved 2017-02-28.
  8. ↑ "SEC Filings | Proteon Therapeutics Inc". Ir.proteontherapeutics.com. Retrieved 2017-02-28.
  9. ↑ Lange, Chris (2016-12-13). "Proteon Therapeutics Craters on Missed Late-Stage Results (NASDAQ: PRTO) - 24/7 Wall St". 24/7 Wall St. Retrieved 2017-02-28.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.